<DOC>
	<DOCNO>NCT02443298</DOCNO>
	<brief_summary>The objective trial primarily evaluate efficacy safety BI 655066/ABBV-066 ( risankizumab ) compare placebo 24-week treatment period severe asthma patient . The primary endpoint time first asthma worsen plan 24 week treatment period active vs. placebo treat patient top standard care therapy . Upon demonstration meaningful clinical response , another important objective identification biomarkers use target patient likely respond treatment BI 655066/ABBV-066 ( risankizumab ) .</brief_summary>
	<brief_title>Efficacy Safety BI 655066/ABBV-066 ( Risankizumab ) Patients With Severe Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : 1 . Prebronchodilator clinic measure FEV1 =40 % =85 % predict normal . 2 . One year history asthma diagnose physician , FEV1 reversibility = 12 % absolute change least 200 mL administration 400 µg salbutamol . 3 . Must least medium dose inhaled corticosteroid least one asthma controller medication least one year . 4 . Must document history two severe asthma exacerbation last 12 month . Exclusion criterion : 1 . Patients significant disease asthma . 2 . Patients able produce sputum sputum sample sufficient quality . 3 . Patients clinically relevant history intubation asthma exacerbation past year . 4 . Patients diagnose concurrent respiratory disease . 5 . Recent history ( within 6 month ) myocardial infarction hospitalize cardiac failure past year . 6 . Patients undergone thoracotomy pulmonary resection . 7 . Patients undergone bronchial thermoplasty radiotherapy procedure past year plan procedure study . 8 . Patients take oral corticosteroid total daily dose 20 mg prednisone ( equivalent ) past 6 week . 9 . Pregnant nursing woman . 10 . Women childbearing potential , sexually active , unwilling use highly effective method birth control . 11 . Clinically relevant acute infection chronic infection . 12 . Have receive live bacterial live viral vaccination last12 week . 13 . Have receive Bacille CalmetteGuerin ( BCG ) vaccination last 12 month . 14 . Have receive treatment ustekinumab ( Stelara® ) . 15 . Have receive treatment biologics last 3 month within 6 time halflife compound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>